Is there a generic version of Rozebalamin (methylcobalamin)?

Currently, Rozebalamin (methylcobalamin), as a treatment for neurological diseases such as amyotrophic lateral sclerosis (ALS), is mainly produced and sold by Japan's Eisai Co., Ltd. (Eisai), and the drug has not yet received widespread generic drug approval worldwide. In Japan, Rozebalamin has been approved for marketing and is mainly used as a treatment for ALS, but generic drugs are not yet common in other regions. While there are some medications that use methylcobalamin as the main ingredient, they are not directly equivalent to generic versions of Rozebalamin and therefore should not be considered direct substitutes.

Because methylcobalamin is produced in the form of freeze-dried powder and requires stricter production standards, the production threshold for its imitations is higher. In addition, the stability, efficacy and efficacy of the drug may be different from the original drug. Even though there may be generic versions of methylcobalamin on the market launched in some countries, their efficacy and safety often require further clinical trials and approval. Therefore, at this stage, original drugs are still the main treatment option.

For patients who need to treat diseases such as ALS, purchasing the original drug Rozebalamin through legal channels is currently a safer and feasible option. In China, because the drug is not yet on the market, patients can only purchase it through overseas channels. It is worth noting that when purchasing drugs overseas, patients should ensure that the purchase channel is legal and choose a certified drug supplier to avoid purchasing counterfeit or inferior drugs, which will affect the treatment effect.

At present, although there is a large demand for methylcobalamin in the global market, generic drugs have not yet become a common substitute due to the patent protection and high production requirements of drugs. In the future, as time goes by and related technologies mature, more generic drugs may enter the market, but this still requires approval and supervision by the drug regulatory agencies of various countries. When choosing drugs, patients should always give priority to the efficacy and safety of the drug and avoid blindly choosing unverified generic drugs to ensure optimal treatment effects. During the purchase process, patients also need to pay special attention to the storage requirements, instructions for use, and the formality of the purchase channels.

xa0

Reference materials:

[1]https://pins.japic.or.jp/pdf/newPINS/00071540.pdf

[2]https://www.eisai.com/news/2024/news202487.html